Date:10/29/2009

======== Notes: (b) Includes costs to tender $75 million of the Company's 4.85% $150 million Senior Notes and other financing-related costs totaling $1.8 million during the nine months ended September 30, 2009. (c) Includes a restructuring charge of $28.4 million which primarily represents severance and lease termination costs during the nine months ended September 30, 2009. (d) Adjusted operating income decreased 11% as compared to the same period in 2008. METTLER-TOLEDO INTERNATIONAL INC. CONDENSED CONSOLIDATED BALANCE SHEETS (amounts in thousands) (unaudited) September 30, 2009 December 31, 2008 Cash and cash equivalents $113,948 $78,073 Accounts receivable, net 284,965 348,614 Inventory 164,761 170,613 Other current assets and prepaid expenses 84,842 73,565 ------ ------ Total current assets 648,516 670,865 Property, plant and equipment, net 303,219 285,008 Goodwill and other intangibles 526,003 520,721 Other non-current assets 202,957 187,462 ------- ------- Total assets $1,680,695 $1,664,056 ========== ========== Short-term debt $10,652 $12,492 Accounts payable 92,010 111,442 Accrued and other current liabilities 321,760 300,938
'/>"/>

SOURCE Mettler-Toledo International Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase